Spravato, a depression treatment derived from club drug ketamine, was looking like a dud. Its recent success now shows a path forward for psychedelic-based medicines.
Related Posts
London-Listed Companies Given More Freedom to Boost Top Executives Wages
The Investment Association simplified its principles of remuneration after a review aimed at ensuring that the U.K. markets continue to attract high-quality companies.
Altria Submits Application for On! Plus Nicotine Pouches to FDA
Altria Group said its wholly owned subsidiary Helix Innovations submitted the application for three on! Plus varieties, tobacco, mint and wintergreen.
Boeing to Sell at Least $10 Billion in Shares to Plug Cash Drain
The jet maker moves to raise much needed cash and secures a new credit line amid paralyzing machinist strike.